Scilex Holding Company reported a binding term sheet for a proposed $100 million strategic investment from iHolding Group LLP, a private investment group based in Almaty, Kazakhstan, an agreement that coincided with a 7% rise in Scilex shares on Monday.
Under the terms laid out in the term sheet, iHolding would acquire newly issued Scilex common stock at a price of $15.00 per share. The purchase price equates to approximately 6.7 million shares. Company statements say the capital infusion is intended to back strategic growth initiatives across several fronts, including expansion of healthcare and medical technology programs, product development and commercialization, potential acquisitions, and general working capital needs.
The proposed transaction remains contingent on a number of conditions. Those include completion of due diligence, negotiation and execution of definitive agreements, board approvals, and other customary closing conditions. The company specifically noted that approval from Scilex stockholders and any required regulatory approvals would also be necessary before the investment could be completed.
Scilex’s stated business focus centers on acquiring, developing, and commercializing non-opioid pain management products for both acute and chronic pain, in addition to therapies aimed at neurodegenerative and cardiometabolic disease. The company framed the proposed investment as a means to accelerate those programs and to support commercialization and corporate development activities.
iHolding Group LLP is described by Scilex as a private investment vehicle with an investment remit that includes healthcare, technology, and cross-border strategic transactions. Scilex noted that the proposed investment represents one of the largest healthcare investments originating from Kazakhstan into a U.S.-listed biopharmaceutical company in recent years, according to the company.
Market reaction to the announcement was immediate, with Scilex shares rising 7% on the day the term sheet was disclosed. The definitive completion of the investment, however, depends on the successful closing of the items outlined in the term sheet and agreed contracts.
The proposed funding, if completed, would provide Scilex with additional capital to pursue its stated growth priorities. Observers should note the multi-step nature of the process from term sheet to closing - the investment remains proposed rather than finalized until all conditions are satisfied.